Interpace Biosciences, Inc. (IDXG)
| Market Cap | 35.41M+593.6% |
| Revenue (ttm) | 36.14M |
| Net Income | 24.86M |
| EPS | 4.50 |
| Shares Out | 5.90M |
| PE Ratio | 1.33 |
| Forward PE | -40.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 131 |
| Open | 6.00 |
| Previous Close | 6.03 |
| Day's Range | 6.00 - 6.00 |
| 52-Week Range | 0.81 - 7.80 |
| Beta | 0.63 |
| Analysts | none |
| Price Target | n/a |
| Earnings Date | n/a |
Insiders here have filed 3 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About IDXG
Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
$IDXG stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in IDXG holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IDXG's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IDXG Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New IDXG patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IDXG from public contracts
Source: USAspending.gov
IDXG Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from IDXG’s recent data — informational, not investment advice